Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations

References

• Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–246. doi:10.3324/haematol.2012.072645
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Wilson NR, Khoury JD, et al. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021;138(15):1373–1377. doi:10.1182/blood.2021011817
   PubMed Web of Science ®Google Scholar
• Reimer P, Rüdiger T, Kraemer D, et al. What is CD4 + CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637–646. doi:10.1038/sj.bmt.1704215
   PubMed Web of Science ®Google Scholar
• Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74–79. doi:10.1111/j.1365-2133.2009.09373.x
   PubMed Web of Science ®Google Scholar
• Ishibashi N, Maebayashi T, Aizawa T, et al. Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature. Int J Clin Exp Med. 2015;8(5):8204–8209.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu Y, Nie Y, et al. A new palliative treatment for blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature. J Int Med Res. 2019;47(10):5281–5288. doi:10.1177/0300060519871860
   PubMed Web of Science ®Google Scholar
• Dietrich S, Andrulis M, Hegenbart U, et al. Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011;17(8):1250–1254. doi:10.1016/j.bbmt.2010.12.706
   PubMed Web of Science ®Google Scholar
• Poussard M, Angelot-Delettre F, Deconinck E. Conventional therapeutics in BPDCN patients-do they still have a place in the era of targeted therapies? Cancers (Basel). 2022;14(15):3767. doi:10.3390/cancers14153767
   PubMed Web of Science ®Google Scholar
• Taylor J, Haddadin M, Upadhyay VA, et al. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019;134(8):678–687. doi:10.1182/blood.2019001144
   PubMed Web of Science ®Google Scholar
• Martín-Martín L, López A, Vidriales B, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015;6(22):19204–19216. doi:10.18632/oncotarget.4146
   PubMedGoogle Scholar
• Kharfan-Dabaja MA, Cherry M. Hematopoietic cell transplant for blastic plasmacytoid dendritic cell neoplasm. Hematol Oncol Clin North Am. 2020;34(3):621–629. doi:10.1016/j.hoc.2020.01.009
   PubMed Web of Science ®Google Scholar
• Unteregger M, Valentin A, Zinke-Cerwenka W, et al. Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm. Bone Marrow Transplant. 2013;48(6):799–802. doi:10.1038/bmt.2012.242
   PubMed Web of Science ®Google Scholar
• Pagano L, Valentini CG, Grammatico S, et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188–202. doi:10.1111/bjh.14146
   PubMed Web of Science ®Google Scholar
• Brüggen MC, Valencak J, Stranzenbach R, et al. Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(7):1489–1495. doi:10.1111/jdv.16215
   PubMed Web of Science ®Google Scholar
• Kerr D, 2nd, Zhang L, Sokol L. Blastic plasmacytoid dendritic cell neoplasm. Curr Treat Options Oncol. 2019;20(1):9. doi:10.1007/s11864-019-0605-x
   PubMed Web of Science ®Google Scholar
• Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018;73:21–23. doi:10.1016/j.leukres.2018.08.014
   PubMed Web of Science ®Google Scholar
• Laribi K, Baugier de Materre A, Sobh M, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020;4(19):4838–4848. doi:10.1182/bloodadvances.2020002474
   PubMed Web of Science ®Google Scholar
• Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848–858. doi:10.1182/bloodadvances.2018017517
   PubMed Web of Science ®Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–1784. doi:10.1038/sj.leu.2401903
   PubMed Web of Science ®Google Scholar
• Cangini D, Silimbani P, Cafaro A, et al. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope. Minerva Med. 2020;111(5):467–477. doi:10.23736/S0026-4806.20.07018-4
   PubMed Web of Science ®Google Scholar
• Alkharabsheh O, Frankel AE. Clinical activity and tolerability of SL-401 (tagraxofusp): recombinant diphtheria toxin and interleukin-3 in hematologic malignancies. Biomedicines. 2019;7(1):6. doi:10.3390/biomedicines7010006
   PubMed Web of Science ®Google Scholar
• Kim JS, Jun SY, Kim YS. Critical issues in the development of immunotoxins for anticancer therapy. J Pharm Sci. 2020;109(1):104–115. doi:10.1016/j.xphs.2019.10.037
   PubMed Web of Science ®Google Scholar
• Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–392. doi:10.1182/blood-2014-04-566737
   PubMed Web of Science ®Google Scholar
• Fanny D, Frankel AE, Seilles E, et al. Preclinical studies of SL-401, a targeted therapy directed to the interleukin-3 receptor (IL3-R), in blastic plasmacytoid dendritic cell neoplasm (BPDCN): potent activity in BPDCN cell lines, primary tumor, and in an in vivo model. Blood. 2013;122(21):3942.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia. ClinicalTrials.gov identifier: NCT02113982. https://clinicaltrials.gov/ct2/show/NCT02113982?term=NCT02113982&draw=2&rank=1. Accessed May 24, 2023.
   Google Scholar
• Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–1637. doi:10.1056/NEJMoa1815105
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Sweet KL, Stein AS, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2022;40(26):3032–3036. doi:10.1200/JCO.22.00034
   PubMed Web of Science ®Google Scholar
• Martín-Martín L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174–10181. doi:10.18632/oncotarget.7101
   PubMedGoogle Scholar
• Beziat G, Ysebaert L. Tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN): a brief report on emerging data. Onco Targets Ther. 2020;13:5199–5205. doi:10.2147/OTT.S228342
   PubMed Web of Science ®Google Scholar
• Kapoor P, Greipp PT, Schaefer EW, et al. Idiopathic systemic capillary leak syndrome (Clarkson’s disease): the Mayo Clinic experience. Mayo Clin Proc. 2010;85(10):905–912. doi:10.4065/mcp.2010.0159
   PubMed Web of Science ®Google Scholar
• Avarbock AB, Loren AW, Park JY, et al. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis. Am J Hematol. 2008;83(7):593–595. doi:10.1002/ajh.21180
   PubMed Web of Science ®Google Scholar
• Horino T, Okada D, Inotani S, et al. Denileukin diftitox-induced systemic capillary leak syndrome with acute kidney injury. CEN Case Rep. 2023;12(1):63–67. doi:10.1007/s13730-022-00720-3
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768–1777. doi:10.1038/s41375-018-0210-1
   PubMed Web of Science ®Google Scholar
• Vedala K, Desikan SP, McClain C, 3rd, et al. Capillary leak syndrome from rituximab therapy of lymphoma. J Investig Med High Impact Case Rep. 2020;8:2324709620942372. doi:10.1177/2324709620942372
   Web of Science ®Google Scholar
• Percik R, Nethanel A, Liel Y. Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment. Immunotherapy. 2021;13(8):653–659. doi:10.2217/imt-2020-0332
   PubMed Web of Science ®Google Scholar
• Polishchuk I, Yakobson A, Zemel M, et al. Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy. Immunotherapy. 2021;13(10):807–811. doi:10.2217/imt-2020-0335
   PubMed Web of Science ®Google Scholar
• Izzedine H, Mathian A, Amoura Z, et al. Anticancer drug-induced capillary leak syndrome. Kidney Int Rep. 2022;7(5):945–953. doi:10.1016/j.ekir.2022.02.014
   PubMedGoogle Scholar
• Mertz P, Lebrun-Vignes B, Salem JE, et al. Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. J Allergy Clin Immunol. 2019;143(1):433–436. doi:10.1016/j.jaci.2018.09.001
   PubMed Web of Science ®Google Scholar
• Jeong GH, Lee KH, Lee IR, et al. Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis. J Clin Med. 2019;8(2):143. doi:10.3390/jcm8020143
   PubMed Web of Science ®Google Scholar
• Lin YT, Wong CY, Chang TY, et al. The effect of tetrastarch solution for capillary leak syndrome following allogeneic hematopoietic stem cell transplantation: a report of 2 cases. Hematol Rep. 2021;13(1):8750. doi:10.4081/hr.2021.8750
   PubMedGoogle Scholar
• ELZONRIS® (tagraxofusp-erzs) [prescribing information]. New York, NY: Stemline Therapeutics, Inc.; 2022.
   Google Scholar
• Deconinck E, Anant M, Manteigas D, et al. Preliminary results from an observational multicenter study of patients with blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp in the European expanded access program. Blood. 2022;140(Supplement 1):8115–8116. doi:10.1182/blood-2022-159942
   Google Scholar
• Angelucci E, Deconinck E, Manteigas D, et al. Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: updated results from a European named patient program. Blood. 2023;142(Supplement 1):547–547. doi:10.1182/blood-2023-178734
   Google Scholar
• HOVON. Directive AML [in Dutch]. 2021. https://hovon.nl/_asset/_public/TreatmentGuidelines/TreatmentGuidelines_Leukemia/AML-richtlijn-versie-2021-06-29-definitief.pdf. Accessed December 5, 2023.
   Google Scholar
• Herling M, Bröckelmann P, Cozzio A, et al. Onkopedia. Blastic plasmacytoid dendritic cell neoplasm [in German]. 2022. https://www.onkopedia.com/de/onkopedia/guidelines/blastische-plasmazytoide-dendritische-zellneoplasie-bpdcn/@@guideline/html/index.html. Accessed December 14, 2023.
   Google Scholar
• Rivoli G, Beltrami G, Raiola A, et al. Tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with/without central nervous system involvement and intrathecal chemotherapy as primary treatment or prophylaxis: an Italian experience. HemaSphere. 2022;6:429–430. Abstract P530. doi:10.1097/01.HS9.0000845008.01963.5f
   Google Scholar
• Sun W, Liu H, Kim Y, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. J Hematol Oncol. 2018;11(1):61. doi:10.1186/s13045-018-0604-6
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Cuglievan B, Lasky J, et al. Treatment of blastic plasmacytoid dendritic cell neoplasm in pediatric patients with tagraxofusp, a CD123-targeted therapy. HemaSphere. 2022;6:420–421. Abstract P521. https://journals.lww.com/hemasphere/fulltext/2022/06003/p521__treatment_of_blastic_plasmacytoid_dendritic.420.aspx
   Google Scholar
• Pemmaraju N, Kantarjian H, Sweet K, et al. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023;141(6):567–578. doi:10.1182/blood.2022017865
   PubMed Web of Science ®Google Scholar
• Elzonris [summary of product characteristics]. Amsterdam, the Netherlands: Stemline Therapeutics B.V.; 2021. https://www.ema.europa.eu/en/documents/product-information/elzonris-epar-product-information_en.pdf. Accessed December 14, 2023.
   Google Scholar
• Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4(16):4020–4027. doi:10.1182/bloodadvances.2019000173
   PubMed Web of Science ®Google Scholar
• Morin A, Kechedjian F, Walton P, et al. Tagraxofusp treatment: implications for patients with blastic plasmacytoid dendritic cell neoplasm. Clin J Oncol Nurs. 2021;25(2):E10–E16. doi:10.1188/21.CJON.E10-E16
   PubMed Web of Science ®Google Scholar
• Horvath LE, Yordan E, Malhotra D, et al. Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. J Oncol Pract. 2010;6(6):e21–e26. doi:10.1200/JOP.2010.000073
   PubMedGoogle Scholar
• Muñoz R, Farshidpour L, Chaudhary UB, et al. Multidisciplinary cancer care model: a positive association between oncology nurse navigation and improved outcomes for patients with cancer. Clin J Oncol Nurs. 2018;22(5):E141–E145. doi:10.1188/18.CJON.E141-E145
   PubMed Web of Science ®Google Scholar
• Taberna M, Moncayo FG, Jané-Salas E, et al. The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020;10:85. doi:10.3389/fonc.2020.00085
   PubMed Web of Science ®Google Scholar
• Sapienza MR, Fuligni F, Agostinelli C, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28(8):1606–1616. doi:10.1038/leu.2014.64
   PubMed Web of Science ®Google Scholar
• Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7(2):156–164. doi:10.1158/2159-8290.CD-16-0999
   PubMed Web of Science ®Google Scholar
• Togami K, Pastika T, Stephansky J, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019;129(11):5005–5019. https://doi.org/10.1172/JCI128571
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. SL-401 in combination with azacitidine or azacitidine/venetoclax in acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). ClinicalTrials.gov identifier: NCT03113643. https://clinicaltrials.gov/ct2/show/NCT03113643?term=NCT03113643&draw=2&rank=1. Accessed May 24, 2023.
   Google Scholar
• Lane AA, Stein AS, Garcia JS, et al. Safety and efficacy of combining tagraxofusp (SL-401) with azacitidine or azacitidine and venetoclax in a phase 1b study for CD123 positive AML, MDS, or BPDCN. Blood. 2021;138(Supplement 1):2346–2346. doi:10.1182/blood-2021-147486
   Google Scholar
• ClinicalTrials.gov. Venetoclax, SL-401, and chemotherapy for the treatment of blastic plasmacytoid dendritic cell neoplasm. ClinicalTrials.gov identifier: NCT04216524. https://clinicaltrials.gov/ct2/show/NCT04216524?term=NCT04216524&draw=2&rank=1. Accessed May 25, 2023.
   Google Scholar
• ClinicalTrials.gov. Study of tagraxofusp for post-transplant maintenance for patients with CD 123+ AML, MF and CMML (HSCT 002). ClinicalTrials.gov identifier: NCT05233618. https://clinicaltrials.gov/ct2/show/NCT05233618?term=NCT05233618&draw=2&rank=1. Accessed May 25, 2023.
   Google Scholar